Catalog No.
FHJ33920
Species reactivity
Human
Host species
Mouse
Isotype
IgG1, kappa
Clonality
Monoclonal
Conjugation
Unconjugated
Target
A8, Semaphorin-4D, GR3, BB18, SEMAJ, C9orf164, CD100, SEMA4D
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q92854
Applications
FCM, FuncS, Neutralization
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.09% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA0331
Regulation of Vascular Calcification by M1-Type Macrophage-Derived Semaphorin 4D., PMID:40507881
Pepinemab: a SEMA4D antagonist for treatment of Huntington's and other neurodegenerative diseases., PMID:40007468
A phase 1/2 study of pepinemab in children, adolescents, or young adults with recurrent or refractory solid tumors: A children's oncology group consortium report (ADVL1614)., PMID:38520670
Sema4D as a biomarker for Predicting rheumatoid arthritis disease activity., PMID:38097864
Sema4D silencing increases the sensitivity of nivolumab to B16-F10 resistant melanoma via inhibiting the PI3K/AKT signaling pathway., PMID:37096066
Impact of leptin or melatonin on Sema4D overexpression-related bone metabolism., PMID:37031174
[The role of semaphorin 4D in the mechanism of bisphosphonate-related osteonecrosis of the jaw in rats]., PMID:36970799
Ophthalmic Solution of Smart Supramolecular Peptides to Capture Semaphorin 4D against Diabetic Retinopathy., PMID:36437109
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial., PMID:35941373
Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity., PMID:35933420
An antagonistic monoclonal anti-Plexin-B1 antibody exerts therapeutic effects in mouse models of postmenopausal osteoporosis and multiple sclerosis., PMID:35850304
SEMA4D/PlexinB1 promotes AML progression via activation of PI3K/Akt signaling., PMID:35794581
Dual-Function Semaphorin 4D Released by Platelets: Suppression of Osteoblastogenesis and Promotion of Osteoclastogenesis., PMID:35328359
Inhibition of RANKL and Sema4D improves residual ridge resorption in mice., PMID:35260755
Anti-Semaphorin 4D Rescues Motor, Cognitive, and Respiratory Phenotypes in a Rett Syndrome Mouse Model., PMID:34502373
Effects of NRP1 on angiogenesis and vascular maturity in endothelial cells are dependent on the expression of SEMA4D., PMID:32945351
Pathological and therapeutic implications of eosinophil-derived semaphorin 4D in eosinophilic chronic rhinosinusitis., PMID:32035658
Inhibition of Sema4D/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy., PMID:31943789
CD Maps-Dynamic Profiling of CD1-CD100 Surface Expression on Human Leukocyte and Lymphocyte Subsets., PMID:31708916
Targeting Semaphorin 4D in Cancer: A Look from Different Perspectives., PMID:31615809
Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents., PMID:31239269
Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition., PMID:31105696
CD100-plexin-B1 induces epithelial-mesenchymal transition of head and neck squamous cell carcinoma and promotes metastasis., PMID:30981760
A high-sensitivity enzyme immunoassay for the quantification of soluble human semaphorin 4D in plasma., PMID:30879960
CD100 Effects in Macrophages and Its Roles in Atherosclerosis., PMID:30324109
[Establishment of a chemiluminescent immunoassay(CLIA) and its application]., PMID:29973321
The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis., PMID:29971044
Semaphorin 4D promotes inhibitory synapse formation and suppresses seizures in vivo., PMID:29799628
Semaphorin 4D from CD15+ Granulocytes via ADAM10-Induced Cleavage Contributes to Antibody Production in Bullous Pemphigoid., PMID:29054606
Intact CD100-CD72 Interaction Necessary for TCR-Induced T Cell Proliferation., PMID:28713384
Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoimmune vasculitis., PMID:28416516
Isolating Fc-Tagged SEMA4D Recombinant Protein from 293FT Cells., PMID:27787840
Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ)., PMID:27720716
Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis., PMID:26883681
The role of Sema4D/CD100 as a therapeutic target for tumor microenvironments and for autoimmune, neuroimmune and bone diseases., PMID:26732941
Soluble SEMA4D/CD100: A novel immunoregulator in infectious and inflammatory diseases., PMID:26732857
Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials., PMID:26566052
Generation and preclinical characterization of an antibody specific for SEMA4D., PMID:26431358
Tax and Semaphorin 4D Released from Lymphocytes Infected with Human Lymphotropic Virus Type 1 and Their Effect on Neurite Growth., PMID:26389656
CD8low CD100- T Cells Identify a Novel CD8 T Cell Subset Associated with Viral Control during Human Hantaan Virus Infection., PMID:26378166
Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications., PMID:25707877
Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease., PMID:25662335
Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody., PMID:25657333
Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies., PMID:25614511
Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment., PMID:25395071
CD72 negatively regulates mouse mast cell functions and down-regulates the expression of KIT and FcεRIα., PMID:25239131
Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients., PMID:24603190
Phage display identification of CD100 in human atherosclerotic plaque macrophages and foam cells., PMID:24098722
Elevated plasma soluble Sema4D/CD100 levels are associated with disease severity in patients of hemorrhagic fever with renal syndrome., PMID:24040126
The class 4 semaphorin Sema4D promotes the rapid assembly of GABAergic synapses in rodent hippocampus., PMID:23699507
For research use only. Not for human or drug use.
